Children taking GLP-1 medications for weight management, prediabetes, or type 2 diabetes may face an underappreciated side effect: nutritional deficiencies. A study published in Childhood Obesity reports that nearly one in six patients—16.8%—received such a diagnosis within the first year of treatment.
The analysis, covered by Medical Xpress, specifically flags vitamin D deficiency as a concern, though the broader pattern suggests the drugs' appetite-suppressing effects may reduce intake of essential nutrients. The authors call for closer nutritional surveillance in this younger population, who are often on long-term therapy.
While the study does not establish causation, the prevalence is high enough to warrant clinical attention. Clinicians may need to consider routine screening and proactive supplementation when prescribing GLP-1s to children, balancing the drugs' metabolic benefits against their potential to compromise growth and development. Further research is needed to clarify which deficiencies are most common and how to mitigate them safely.